362483-75-8

Basic information

• Product Name: 3-(3-chloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one
• Synonyms: 3-(3-chloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one
• CAS NO: 362483-75-8
• Molecular Weight: 226.66
• Mol File: 362483-75-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(3-chloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-chloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one(362483-75-8)
• EPA Substance Registry System: 3-(3-chloro-phenyl)-5-hydroxymethyl-dihydro-furan-2-one(362483-75-8)

Safety Data

• Hazardous Substances Data: 362483-75-8(Hazardous Substances Data)

Upstream product

• 362483-68-9 methyl 2-(3-chlorophenyl)pent-4-enoate 
• 53088-68-9 methyl 3-chlorophenylacetate 
• 1878-65-5 3-chlorophenylacetic acid 
• 619254-67-0 2-(3-chlorophenyl)pent-4-enoic acid 

Downstream Products

• 362483-87-2 5-(tert-butyl-dimethyl-silanyloxymethyl)-3-(3-chloro-phenyl)-5H-furan-2-one 
• 362483-23-6 3-(3-chlorophenyl)-5-hydroxymethyl-2H,5H-furan-2-one 
• 362483-83-8 5-(tert-butyl-dimethyl-silanyloxymethyl)-3-(3-chloro-phenyl)-dihydro-furan-2-one 

Relevant articles and documents

3-Phenyl-5-acyloxymethyl-2H,5H-furan-2-ones: Synthesis and biological activity of a novel group of potential antifungal drugs

3-(Substituted phenyl)-5-acyloxymethyl-2H,5H-furan-2-ones related to the natural product (-)-incrustoporine were synthesized and their in vitro antifungal activity evaluated. The compounds with halogen substituents on the phenyl ring displayed much higher antifungal effect against Aspergillus fumigatus than selected representatives of azole antifungal drugs. In particular, the activity (1.34 μg/mL) of the most promising derivative, 3-(3,4-dichlorophenyl)-5-pivaloyloxymethyl-2H,5H-furan-2-one, was comparable to that of amphotericin B (0.5 μg/mL). Preliminary evaluation of the toxicity of the compound was carried out as well. Considering the size and properties of these molecules in comparison with those of amphotericin B, further development of this novel group of antifungals may lead to substances with better pharmacological profiles than that of the standard anti-Aspergillus drug.